Shanghai Hutchison Pharmaceuticals Limited
Clinical trials sponsored by Shanghai Hutchison Pharmaceuticals Limited, explained in plain language.
Develops and commercializes oncology and immunology drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to boost stroke recovery in major trial Results expected Jun 2027 (estimated)
-
Herbal pill shows promise for neck nerve pain in new trial
Disease control CompletedThis study tested whether a Chinese herbal pill called Shenqi Sherong Pill can help people with mild to moderate cervical spondylotic myelopathy, a condition where the spinal cord in the neck is compressed. 428 adults aged 18-75 took either the herbal pill or a placebo three time…
Phase 3 • Sponsor: Shanghai Hutchison Pharmaceuticals Limited • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New stroke drug shows promise in early trial
Disease control CompletedThis study tested a new drug called SHPL-49 in 270 people who had an acute ischemic stroke. Participants received either the drug or a placebo as an IV infusion twice daily for 7 days. The goal was to see if the drug helps improve recovery and is safe to use.
Phase 2 • Sponsor: Shanghai Hutchison Pharmaceuticals Limited • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC